

Re: Your request made under the Freedom of Information Act 2000

Q1. How many patients were treated in the last 4 months (April to July 2023) by the dermatology department with each of the following products:

- Abrocitinib - 0
- Acitretin - 46
- Alitretinoin - 1
- Azathioprine - 2
- Baricitinib - 2
- Ciclosporin - 13
- Dupilumab - 21
- Methotrexate - 130
- Mycophenolate mofetil - 9
- Pimecrolimus - 2
- Phototherapy (UVB or PUVA) - 0
- Tacrolimus ointment - 16
- Tralokinumab - 0
- Upadacitinib - 0

Q2. How many patients were treated by the dermatology department in the previous 4-month period (December 22 - March 23) with Dupixent?

16

Q3. For patients treated by the dermatology department with Dupilumab in the four months from December 22 to March 2023, could you please tell us:

- a. How many patients were treated in the subsequent 4-month period (April - July 23) with Dupilumab?
- b. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following advanced therapies - Abrocitinib, Baricitinib, Tralokinumab and Upadacitinib?
- c. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following immunosuppressants - Methotrexate, Ciclosporin, Mycophenolate or Azathioprine?
- d. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following - Acitretin, Alitretinoin, Pimecrolimus or Tacrolimus?

•

Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Our Ref: 398/2023
AUGUST 2023